Shared Chat

In-Between Company Valuation

Read-only conversation

"Do you think the market ignores “in-between” companies? Discussion There seems to be a gap between very focused companies and very large diversified ones. The “in-between” type — small companies trying to expand into multiple directions — don’t always get much attention. TROO is one I came across that kind of sits in that middle zone, at least from what I’ve seen so far. Not forming a strong view, just observing how those types of companies usually get treated."

Yes, the "in-between" zone is a real phenomenon, often called the "mid-cap orphan" or "diworsification discount" problem. A few reasons it happens:

Analyst coverage gap — Too small for big-bank coverage, too sprawling for small-cap specialists who prefer pure-play stories.
Index ineligibility — Often miss the size cutoff for S&P 500 inclusion but are too big to move on Russell 2000 flows.
Narrative friction — Funds bucket money by theme (AI, biotech, energy). A company doing three things at once doesn't fit any one fund's mandate cleanly.
Execution risk premium — Multi-direction expansion burns capital before any single line proves out, so the market discounts each segment.
Sum-of-parts opacity — Hard to value with one multiple, and sum-of-parts analyses rarely move the price until a spin-off forces it.

Let me check TROO specifically since you mentioned it.

TROO is actually a good illustration of your thesis, but it's a more extreme case than typical "mid-cap orphan":

~$448M market cap, 42 employees, beta 3.7 — micro-cap, not mid-cap
Sprawled across mortgage lending (HK/Australia), a fintech marketplace, SaaS/app dev consulting, and real estate leasing — four unrelated businesses
Renamed from SGOCO Group in 2021 — name changes often signal strategic drift
52-week range $0.53–$5.28 — that volatility is the market's verdict: no stable valuation anchor

So TROO isn't really being "ignored" — it's being priced as a low-conviction grab bag. That's different from the orphan dynamic, where a quality business gets a discount purely from poor fit. Here, the conglomerate structure at micro-cap scale is itself the problem: no segment has enough capital to win, and investors can't underwrite four theses at once.

The nuance worth holding: the orphan thesis works best when you find a profitable, cash-generating multi-line business that's simply mis-bucketed (think Markel, Berkshire in its early days, or smaller industrial conglomerates). It rarely works for sub-$500M companies still searching for a business model — there, the diversification usually reflects management indecision, not hidden value.

Worth observing, as you said, but I'd separate "ignored quality" from "correctly skeptical of strategic incoherence."

This response may contain financial commentary based on historical data and does not constitute investment advice. Past performance is not indicative of future results. Please consult a qualified financial advisor before making investment decisions.